Teleflex (TFX) Investor Update summary

Strategic rationale and integration progress

• Acquisition of Vascular Intervention business creates a comprehensive portfolio in coronary and peripheral intervention, leveraging synergies in engineering, manufacturing, and commercial execution.

• The combined business is positioned for global growth, focusing on expanding commercial reach, integrating sales forces, and converting distributors to direct sales.

• Integration milestones are on track, with ongoing focus over the next 12-18 months to drive strong growth and operational efficiencies.

• Recent acquisition expands market presence, enhances product synergies, and improves global reach, with integration activities ongoing to drive growth.

• Revenue synergies are expected as the combined sales force increases global presence and customer engagement.

Market trends and growth drivers

• Global coronary heart disease and peripheral vascular disease incidence and prevalence are projected to rise sharply by 2050, driving demand for advanced interventions.

• Peripheral markets are growing in the upper single digits, with the business already outpacing market growth at 7% in the last quarter.

• High single-digit growth expected in peripheral intervention, driven by rising disease complexity and aging populations.

• Global total addressable market for vascular intervention estimated at $10bn, with coronary interventions representing 64% and peripheral 36%.

• The complex PCI and CTO subsegment is a primary focus, offering faster growth and high-value engagement opportunities.

Product portfolio and innovation pipeline

• The portfolio spans access, procedural enablement, and therapeutics, including best-in-class drug-eluting stents, drug-coated balloons, covered stents, and resorbable magnesium scaffolds.

• Orsiro Mission DES is a differentiated, ultra-thin strut stent with strong clinical evidence and expansion plans for larger diameters and longer lesions.

• Freesolve RMS, a resorbable magnesium scaffold, is positioned as a transformative technology with ongoing clinical trials (BIOMAG series) and FDA breakthrough designation for below-the-knee use.

• Pipeline includes new high-pressure balloons, crossing balloons, and digital health solutions for chronic limb-threatening ischemia.

• Robust R&D pipeline targets expansion into new, high-growth segments, with near-term and longer-term product launches planned.